Australia markets closed

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
18.57-0.10 (-0.54%)
At close: 04:00PM EDT
18.50 -0.07 (-0.38%)
After hours: 07:58PM EDT

uniQure N.V.

Paasheuvelweg 25a
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 463

Key executives

NameTitlePayExercisedYear born
Mr. Matthew Craig KapustaCEO & Exec. Director969.95kN/A1972
Mr. Christian KlemtCFO, Principal Financial Officer & GM of Amsterdam Site505.02kN/A1973
Mr. Pierre CalozChief Operating Officer714kN/AN/A
Dr. Alexander E. Kuta Ph.D.Exec. VP of Quality & Regulatory Affairs649.26k1.42M1960
Dr. Ricardo Dolmetsch Ph.D.Pres of R&D795.35kN/A1969
Prof. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-GermanyN/AN/AN/A
Mr. David CervenyChief Legal Officer, Gen. Counsel & Sec.N/AN/A1967
Dr. Tamara Tugal Ph.D., MBABus. Devel. DirectorN/AN/AN/A
Ms. Erin BoyerChief People & Culture OfficeN/AN/AN/A
Ms. Maria E. CantorChief Corp. Affairs OfficerN/AN/A1968
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate governance

uniQure N.V.’s ISS governance QualityScore as of 1 June 2022 is 3. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 2; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.